Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Dr Sherin Al-Safadi appointed VP Medical & Corporate Affairs

Thursday, July 20, 2023 1 min read
Key Takeaway: Dr. Sherin Al-Safadi has been appointed as the Vice President of Medical and Corporate Affairs at Radiopharm Theranostics. Her extensive background in medical affairs is anticipated to strengthen the company's strategic initiatives. This leadership change is part of Radiopharm's ongoing efforts to enhance its position in the biopharma industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Sherin Al-Safadi's appointment is expected to enhance corporate strategy.
  • Her experience in medical affairs will benefit Radiopharm Theranostics.
  • The appointment reflects the company's commitment to leadership in the sector.

Full Press Release Details

• Announcements
• July 20, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• August 14, 2024
• Announcements
• October 20, 2022
• Announcements
• February 14, 2024
• Announcements
• February 28, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

Who is Dr. Sherin Al-Safadi?

Dr. Sherin Al-Safadi is the newly appointed Vice President of Medical and Corporate Affairs at Radiopharm Theranostics.

What role will Dr. Al-Safadi play at Radiopharm?

Dr. Al-Safadi will enhance the company's corporate strategy and medical affairs.

Why is Dr. Al-Safadi's appointment significant?

Her extensive experience is expected to strengthen Radiopharm's position in the biopharma industry.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics Dr. Sherin Al-Safadi VP Medical Affairs leadership change biopharma news
Last updated: Jul 20, 2023